The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Sanofi's (NASDAQ:SNY) Dupixent (dupilumab) as add-on maintenance treatment for patients at least 12 years old with certain types of severe asthma.
Dupixent is currently approved in Europe for atopic dermatitis.
A final decision from the European Commission usually takes ~60 days.
SNY is up 1% premarket on light volume.
Related ticker: Regeneron Pharmaceuticals (NASDAQ:REGN)
Subscribe for full text news in your inbox